Results 1 to 10 of about 78,818 (344)

Protein-based Radiopharmaceuticals that target fibroblast activation protein alpha: a review of current progress [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Fibroblast activation protein alpha (FAP) is a serine protease that is expressed at basal levels in benign tissues but is overexpressed in a variety of pathologies, including cancer.
Abdelrahman Homedan, Darpan N. Pandya, Nicholas J. Schnicker, Thaddeus J. Wadas   +3 more
doaj   +2 more sources

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials

The Oncologist, 2023
Radiopharmaceuticals have been utilized for men with advanced prostate cancer for decades. Older agents, seldom used today, provided palliation for bone metastatic pain.
B. Ramnaraign, O. Sartor
semanticscholar   +1 more source

Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals

International Journal of Molecular Sciences, 2023
Copper-64 (T1/2 = 12.7 h) is a positron and beta-emitting isotope, with decay characteristics suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer.
O. Krasnovskaya, Daniil Abramchuck, A. Erofeev, P. Gorelkin, Alexander Kuznetsov, A. Shemukhin, E. Beloglazkina   +6 more
semanticscholar   +1 more source

Synthesis and comparative evaluation of 177Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes

Scientific Reports, 2022
Highest global cancer incidence of female breast cancer is a matter of great concern. HER2-positive breast cancers have high mortality rate hence detection at an early stage is vital for successful treatment, improved cancer care and survival rate ...
Amit Kumar Sharma, Rohit Sharma, Kusum Vats, Haladhar Dev Sarma, Archana Mukherjee, Tapas Das, Drishty Satpati   +6 more
doaj   +1 more source

DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair

Pharmaceutics, 2023
DNA is an organic molecule that is highly vulnerable to chemical alterations and breaks caused by both internal and external factors. Cells possess complex and advanced mechanisms, including DNA repair, damage tolerance, cell cycle checkpoints, and cell ...
Yousef Khazaei Monfared, P. Heidari, S. Klempner, Umar Mahmood, A. Parikh, Theodore S. Hong, Matthew R Strickland, Shadi A. Esfahani   +7 more
semanticscholar   +1 more source

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade

International Journal of Molecular Sciences, 2022
Positron emission tomography (PET) uses radioactive tracers and enables the functional imaging of several metabolic processes, blood flow measurements, regional chemical composition, and/or chemical absorption.
George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, Gabriel Andrieș, C. Căinap, V. Chiș   +5 more
semanticscholar   +1 more source

Electrochemical separation and purification of no-carrier-added 177Lu for radiopharmaceutical preparation: Translation from bench to bed

Chemical Engineering Journal Advances, 2023
The entry of no-carrier-added (NCA) 177Lu in the arena of clinical nuclear medicine has revolutionized the practice of targeted radionuclide tumor therapy.
Sourav Patra, Rubel Chakravarty, Khajan Singh, K.V. Vimalnath, Sudipta Chakraborty   +4 more
doaj   +1 more source

An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics

Diagnostics, 2023
Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ) radiation through radiation decay. Therefore, they are used in the biomedical field to label biomolecules or drugs for diagnostic imaging applications, such as positron
V. Benfante, A. Stefano, Muhammad Ali, Riccardo Laudicella, W. Arancio, A. Cucchiara, Fabio Caruso, F. Cammarata, C. Coronnello, G. Russo, M. Miele, Alessandra Vieni, A. Tuttolomondo, A. Yezzi, A. Comelli   +14 more
semanticscholar   +1 more source

Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma

EJNMMI Radiopharmacy and Chemistry, 2021
Background There is a need to develop new and more potent radiofluorinated peptide and their hybrid conjugates for multiple-receptors targeting properties that overexpress on many cancers.
I. Al Jammaz, B. Al-Otaibi, Y. Al-Malki, A. Abousekhrah, S. M. Okarvi   +4 more
doaj   +1 more source

Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA

He huaxue yu fangshe huaxue, 2023
A novel PSMA targeting molecule ［177Lu］Lu-DOTA-CPN-PSMA with high uptake and long retention in prostate cancer was developed, in which DOTA was used as the bifunctional chelator, glutamic acid-urea-lysine(Glu-Urea-Lys) was used as the targeting group ...
LUO Tian-wei, SUN Ming-yue, ZHANG Wen-hui, GAO Fei, WANG Ning, HUANG Xu-hu, CHEN Huan, LI Hong-yu   +7 more
doaj   +1 more source